The animal experiments conducted in the present study also revealed that the activity of the AMPK/Sirt1‐PGC‐1α‐TFAM pathway was reduced in mice with COPD and that rhCC16 administration activated this pathway and mitigated COPD‐like symptoms. This evidence concerns the gene PPARGC1A and chronic obstructive pulmonary disease.